Online inquiry

IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ117MR)

This product GTTS-WQ117MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ117MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2771MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ14973MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ3598MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ4046MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ13800MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ9569MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ14909MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ1175MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABP 501
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW